Business Description
Larimar Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US5171251003
Description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.99 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.9 | |||||
| 3-Year EPS without NRI Growth Rate | 38.3 | |||||
| 3-Year FCF Growth Rate | 40.1 | |||||
| 3-Year Book Growth Rate | -31.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -32.26 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.82 | |||||
| 9-Day RSI | 72.53 | |||||
| 14-Day RSI | 67.82 | |||||
| 6-1 Month Momentum % | -22.82 | |||||
| 12-1 Month Momentum % | 101.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.1 | |||||
| Quick Ratio | 13.1 | |||||
| Cash Ratio | 12.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.9 | |||||
| Shareholder Yield % | -28.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -39.73 | |||||
| ROA % | -35.81 | |||||
| ROIC % | -825.62 | |||||
| 3-Year ROIIC % | -160.43 | |||||
| ROC (Joel Greenblatt) % | -1977.77 | |||||
| ROCE % | -44.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.87 | |||||
| Price-to-Tangible-Book | 2.87 | |||||
| EV-to-EBIT | -5.03 | |||||
| EV-to-EBITDA | -5.05 | |||||
| EV-to-FCF | -6.36 | |||||
| Price-to-Net-Current-Asset-Value | 2.96 | |||||
| Price-to-Net-Cash | 3.1 | |||||
| Earnings Yield (Greenblatt) % | -19.88 | |||||
| FCF Yield % | -10.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Larimar Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.046 | ||
| Beta | 1.61 | ||
| Volatility % | 116.14 | ||
| 14-Day RSI | 67.82 | ||
| 14-Day ATR (€) | 0.296852 | ||
| 20-Day SMA (€) | 6.78 | ||
| 12-1 Month Momentum % | 101.05 | ||
| 52-Week Range (€) | 2.16 - 12.2 | ||
| Shares Outstanding (Mil) | 63.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Larimar Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Larimar Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Larimar Therapeutics Inc Frequently Asked Questions
What is Larimar Therapeutics Inc(FRA:ZA71)'s stock price today?
The current price of FRA:ZA71 is €8.10. The 52 week high of FRA:ZA71 is €12.20 and 52 week low is €2.16.
When is next earnings date of Larimar Therapeutics Inc(FRA:ZA71)?
The next earnings date of Larimar Therapeutics Inc(FRA:ZA71) is 2024-11-14 Est..
Does Larimar Therapeutics Inc(FRA:ZA71) pay dividends? If so, how much?
Larimar Therapeutics Inc(FRA:ZA71) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers